Old drugs, new trick: can leukemia meds supercharge cancer immunotherapy?
NCT ID NCT05276284
Summary
This study tested if adding two older leukemia drugs (6MP and 6TG) to a modern immunotherapy drug (atezolizumab) could help control advanced solid tumors. The idea was that the older drugs might cause more mutations in the cancer, making it more visible to the immune system. It involved a small group of adults with advanced cancer that had not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.